Arecor Limited has extended a multi-product collaboration with a US-based biotech company to develop products for oncology and a rare genetic orphan condition.
Under the collaboration, Arecor said it will leverage its Arestat technology to develop liquid formulations of two proprietary novel products, while its partner is currently funding the development work and has an option to acquire the formulations and associated intellectual property under separate milestone-bearing licenses at pre-agreed financial terms.
READ: Arecor achieves important second, contractual milestone with one of its pharmaceutical partners
Arestat is a formulation technology designed to enhance the properties of therapeutic proteins and peptides.
"This multi-collaboration with a fast growing US biotech company demonstrates the adaptability of the Arestat platform”, said Arecor chief executive Sarah Howell.
“Not only do these key products represent Arestat’s ability to support the development of clinical stage assets across a range of therapeutic areas, but also demonstrate the potential of the technology to deliver superior liquid formulations of novel format proteins, further expanding and advancing the application of Arecor’s expertise across the spectrum of product development”, she added.